The bulk of published work comes from Predrag Sikiric's group at the University of Zagreb, who have produced the majority of BPC-157 publications over three decades
Both reductions in weight and gastrointestinal side-effects were more frequent in the LY3298176 arm than in the other two groups
Clinical trials show retatrutide can reduce body weight by up to 24% after 48 weeks, significantly outperforming many current obesity treatments
References Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al
Indeed, if tirzepatide and other GLP-1 drugs for weight loss become subject to mandatory discounting through the Inflation Reduction Act (by 2031, or sooner if their developers attempt to reduce prices in anticipation of this deadline) or similar regulation, their prices would be directly reduced, making them more affordable